Tier 4 — mechanistic

Homocystinuria: Therapeutic approach

Tarun Kumar, Gurumayum Suraj Sharma, Laishram Rajendrakumar Singh
Clinica chimica acta; international journal of clinical chemistry 2016 458:55-62

Bibliography

PubMed
PMID 27059523
DOI
10.1016/j.cca.2016.04.002
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignNarrative review
ModelEvidence synthesis; mixed research models
SampleClinical and experimental homocystinuria literature
InterventionEstablished and emerging approaches to reducing homocysteine toxicity
DurationLiterature review
EndpointsHomocystinuria treatment; Homocysteine toxicity

What the study showed, in plain terms

Published in 2016, this source examined prescription betaine and inherited metabolic disorders. Its evidence base was Clinical and experimental homocystinuria literature. It evaluated Established and emerging approaches to reducing homocysteine toxicity across Literature review.

Reviews betaine alongside dietary restriction, vitamin therapy and experimental molecular treatments.

A therapeutic overview rather than a new efficacy trial; many emerging approaches are preclinical.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • Reviews betaine alongside dietary restriction, vitamin therapy and experimental molecular treatments.
  • The recorded outcome domains were Homocystinuria treatment; Homocysteine toxicity.

What this study can and cannot tell us

  • A therapeutic overview rather than a new efficacy trial; many emerging approaches are preclinical.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders
Giorgia Olivieri et al. · Journal of inherited metabolic disease · 2026
Tier 2
Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency
Andrew A M Morris et al. · Journal of inherited metabolic disease · 2017
Tier 4
Postauthorization safety study of betaine anhydrous
Ulrike Mütze et al. · Journal of inherited metabolic disease · 2022
Tier 4
Cystathionine beta synthase deficiency and brain edema associated with methionine excess under betaine supplementation: Four new cases and a review of the evidence
Bernd C Schwahn et al. · JIMD reports · 2020
Tier 2
Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial
Apolline Imbard et al. · Orphanet journal of rare diseases · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology